Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liposomal bupivacaine for adductor canal and IPACK block in total knee arthroplasty
ChiCTR2400087410Phase 3Not yet recruiting
- Sponsor
- General Hospital of the Northern Theater Command
- Start
- Jul 2024
- Modality
- Small Molecules, Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, open-label trial of liposomal bupivacaine and bupivacaine in postoperative pain (4 arms), sponsored by General Hospital of the Northern Theater Command. Primary endpoints: Visual analogue scale pain assessment, Area under the NRS pain intensity curve and 1 more. Planned start Jul 2024; status: not yet recruiting.
02
Drugs
liposomal bupivacainebupivacaine
03
Conditions
postoperative pain
Beyond the preview
Go deeper on ChiCTR2400087410.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400087410.